Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Finerenone: intact · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Adult formulation: Finerenone tablet_Fasting | ACTIVE_COMPARATOR | Single oral dose of 20 mg intact finerenone tablet fasting |
| Adult formulation: Finerenone crushed tablet_Fasting | EXPERIMENTAL | Single oral dose of 20 mg crushed and resuspended finerenone tablet fasting |
| Pediatric formulation: Finerenone suspension_Fasting | EXPERIMENTAL | Single oral dose of 20 mg finerenone suspension fasting |
| Pediatric formulation: Finerenone suspension_Fed | EXPERIMENTAL | Single oral dose of 20 mg finerenone suspension fed; 30 minutes after start of an American breakfast |
| Name | Type | Description |
|---|---|---|
| Finerenone (BAY94-8862): 20 mg intact tablet | DRUG | 20 mg intact finerenone immediate-release tablet; single dose in the fasting condition |
| Finerenone (BAY94-8862): 20 mg crushed and resuspended tablet | DRUG | 20 mg crushed and resuspended finerenone immediate-release tablet; single dose in the fasting condition |
| Finerenone (BAY94-8862): 20 mg suspension | DRUG | 20 mg finerenone suspension; single dose in the fasting condition or in the fed condition |
Inclusion Criteria: * Healthy male subjects * Age: 18 to 45 years (inclusive) * Body mass index (BMI) : ≥ 18 and ≤ 29.9 kg/m² * Race: White Exclusion Criteria: * Subjects with conspicuous findings in medical history and pre-study examination in the opinion of the investigator * A history of relev...
Finerenone is a small molecule drug developed by Bayer AG under the ticker BAYRY. It is being studied in clinical development, with a Phase 1 trial completed in healthy male volunteers. The specific medical conditions it is intended to treat have not been disclosed.
Finerenone is developed by Bayer AG, which trades under the ticker BAYRY. Bayer sponsored the Phase 1 study of the drug, a pharmacokinetic trial conducted in Germany in healthy male subjects.
Finerenone is in Phase 1 clinical development. One Phase 1 trial has been completed, and no active trials are currently listed. The completed study was a randomized, active-controlled pharmacokinetic trial in healthy male volunteers.
Finerenone has been studied in one completed clinical trial, NCT02957396, titled Study of Finerenone to Investigate a Paediatric Formulation in Healthy Male Subjects. The Phase 1 trial enrolled 16 healthy male volunteers aged 18 years and older in Germany and used an active-controlled, randomized design.
Yes, finerenone is also known as BAY94-8862. The 20 mg intact tablet is one formulation of the drug. Bayer AG developed finerenone under the code BAY94-8862, and the two names refer to the same small molecule compound.